Peter A. Ljubenkov, MD, is an associate professor of neurology, a behavioral neurologist, and a clinical trialist at the University of California, San Francisco (UCSF) Edward and Pearl Fein Memory Aging Center. He currently serves as the director of the UCSF Alzheimer's Infusion Core (AIC), which manages clinical infusions of anti-amyloid therapies at UCSF. He is also associate director of UCSF’s Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program, and supervises a clinical therapeutics training track within the UCSF Behavioral Neurology Training Program (BNTP) fellowship. Dr. Ljubenkov’s primary research focus is on clinical therapeutic trials and biomarker development to support clinical trials, particularly in patients with forms of frontotemporal lobar degeneration (FTLD). He has led multiple clinical trials in patients with different forms of neurodegenerative disease, including Veri-T (NCT05184569), the first clinical therapeutic trial to focus on patients with semantic variant primary progressive aphasia (svPPA).
Dr. Ljubenkov earned his medical degree at Lewis Katz School of Medicine at Temple University. He completed a residency in neurology at the University of California, San Diego, and a fellowship in behavioral neurology at UCSF before joining the faculty at UCSF in 2018.